Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

about

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung

P2860

Q56891609-B9BBAABC-F16A-4C47-ABA4-14BF32EBC2F4 Q58733942-5A4C0747-61E5-4F2F-91AC-F00BBDAD06E1

P2860

Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Item

http://www.wikidata.org/entity/Q38614840

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Metabolic activity by (18)F-FD ...... b in previously treated NSCLC.

@en

type

Item

label

Metabolic activity by (18)F-FD ...... b in previously treated NSCLC.

@en

prefLabel

Metabolic activity by (18)F-FD ...... b in previously treated NSCLC.

@en

P1476

Metabolic activity by (18)F-FD ...... b in previously treated NSCLC.

@en

P2093

Akira Mogi

http://www.w3.org/2001/XMLSchema#string

Azusa Tokue

http://www.w3.org/2001/XMLSchema#string

Bolag Altan

http://www.w3.org/2001/XMLSchema#string

Hideru Obinata

http://www.w3.org/2001/XMLSchema#string

Ichiro Naruse

http://www.w3.org/2001/XMLSchema#string

Keita Mori

http://www.w3.org/2001/XMLSchema#string

Kimihiro Shimizu

http://www.w3.org/2001/XMLSchema#string

Kyoichi Kaira

http://www.w3.org/2001/XMLSchema#string

Masahiko Nishiyama

http://www.w3.org/2001/XMLSchema#string

Noriaki Sunaga

http://www.w3.org/2001/XMLSchema#string

P2860

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.

Synthesis of 5-[18F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

P2888

s00259-017-3806-1

P31

scholarly article

P356

10.1007/S00259-017-3806-1

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28828507

http://www.w3.org/2001/XMLSchema#string

Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

about

P2860

P2860

Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698